Encorium Group Inc. is a full-service multinational contract research organization (CRO). They provide design, development, and management capabilities for clinical trials and patient registries. They do this for many of the world’s leading pharmaceutical companies. Trading on the NASDAQ Capital Market, Encorium Group Inc. has offices in 10 countries, managing clinical trials with their own employees. The Company’s corporate headquarters are in Wayne, Pennsylvania.
Encorium Group, Inc. provides their services to the pharmaceutical, biotechnology, and medical device industries. Their corporate mission is to provide their clients with high quality, full-service support for their biopharmaceutical and medical device development programs. They offer therapeutic expertise, experienced team management, and advanced technologies.
Encorium has drug and biologics development as well as clinical trial experience across a broad spectrum of therapeutic areas. These include infectious diseases, cardiovascular, vaccines, oncology, and diabetes endocrinology/metabolism. These also include gene therapy, immunology, neurology, gastroenterology, dermatology, hepatology, women’s health and respiratory medicine.
On September 9, 2009, Encorium Group, Inc. reported the signing of approximately $8.7 million of new business contracts. This includes selection by a major pharmaceutical company for participation in a swine flu vaccine program.
On Monday, Encorium Group, Inc. announced that they completed a private placement of 3,937,500 shares of their common stock with a private investor for an aggregate purchase price of $1,575,000, or $.40 per share. Prior to this, the Company executed a Warrant Exchange Agreement.
Dr. Kai Lindevall, Executive Chairman stated, “We are very pleased that we were able to close this financing to shore up our balance sheet and provide the Company with additional working capital. Our experience and capabilities in the vaccine field coupled with the recent new awards in this area demonstrate the long-term potential we have to grow into a leading vaccine franchise with expertise in pre-clinical support, regulatory consultancy and strategic trial planning.”